Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
56518-41-3COc1cc(Cc2cnc(N)nc2N)cc(OC)c1BrBFCRRLMMHNLSCP-UHFFFAOYSA-N56518-41-3DTXSID20205070CHEMBL31891CHEBI:131726BeschreibungBrodimoprim, a dihydrofolate reductase inhibitor, was introduced for the treatment of common infections of upper respiratory tract such as sinusitis and exacerbation of chronic bronchitis. It has a broad spectrum of antimicrobial activities against most Gram-positive and -negative pathogens including some bacterial strains that are resistant to amoxicillin, a widely used antibiotic for the indicated infections. Brodimoprim also has a favorable pharmacokinetic profile exemplified by its long half-life and good tissue penetration.
VerwendenA structural derivative of Trimethoprim (T795615). A selective dihydrofolate reductase inhibitor; diaminopyridine antibacterial agent.
Wird geladen…
DefinitionChEBI: An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.